Epigenomics AG
EPGNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | 0.00 |
| FCF Yield | 0.00% | -1,480.15% | -1,001.55% | -1,213.79% |
| EV / EBITDA | -3.33 | -2.81 | 0.70 | 11.43 |
| Quality | ||||
| ROIC | -116.25% | -33.23% | -107.86% | -10.49% |
| Gross Margin | 0.00% | 83.22% | 75.26% | 97.81% |
| Cash Conversion Ratio | 1.28 | 1.00 | 1.71 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -62.04% | -16.80% | 76.66% |
| Free Cash Flow Growth | 0.00% | 57.32% | -219.78% | 56.35% |
| Safety | ||||
| Net Debt / EBITDA | -3.13 | -2.71 | 0.82 | 11.61 |
| Interest Coverage | 0.00 | 0.00 | -92.70 | -45.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.97 | 0.77 |
| Cash Conversion Cycle | 0.00 | -1,514.22 | -10,514.23 | -873.31 |